Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Research & Development: 2009-2024

Historic Research & Development for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to $113.4 million.

  • Myriad Genetics' Research & Development fell 1.05% to $28.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.5 million, marking a year-over-year increase of 11.82%. This contributed to the annual value of $113.4 million for FY2024, which is 27.85% up from last year.
  • As of FY2024, Myriad Genetics' Research & Development stood at $113.4 million, which was up 27.85% from $88.7 million recorded in FY2023.
  • In the past 5 years, Myriad Genetics' Research & Development ranged from a high of $113.4 million in FY2024 and a low of $73.3 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $88.7 million (2023), whereas its average is $95.8 million.
  • As far as peak fluctuations go, Myriad Genetics' Research & Development declined by 10.13% in 2020, and later rose by 27.85% in 2024.
  • Myriad Genetics' Research & Development (Yearly) stood at $77.2 million in 2020, then reached $73.3 million in 2020, then grew by 11.73% to $81.9 million in 2021, then grew by 4.27% to $85.4 million in 2022, then climbed by 3.86% to $88.7 million in 2023, then rose by 27.85% to $113.4 million in 2024.